International Journal of Pharma and Bio Sciences
ijpbs.net
editorijpbs@rediffmail.com (or) editorofijpbs@yahoo.com (or) prasmol@rediffmail.com
10.22376/ijpbs.2019.10.1.p1-12
Volume 7 Issue 1
2016 (January - March)
NIACIN THERAPY FOR THE TREATMENTOF HYPERPHOSPHATAEMIA IN END STAGERENAL DISEASE PATIENTS
Elevated serum phosphorus is a predictable accompaniment of end-stage renal disease (ESRD) in the absence of supplemental phosphate binders.. We have analyzed the distribution of serum phosphorus in samples of hemodialysis patients who have been receiving dialysis for at least 1 year. Recently, niacin, a traditional antilipemic agent, drew attention as an experimental treatment for Hyperphosphataemia.. Sodium-dependent phosphorus co-transport in the duodenum and jejunum appears to account for at least 50% of intestinal phosphorus absorption. Niacinamide reduces intestinal phosphate absorption by inhibiting the sodium-phosphate transporter in the gastrointestinal tract.The purpose of this study is to report on new findings regarding niacin's novel effects and to review the possibility of repurposing niacin for Hyperphosphataemia treatment in dialysis patients by elucidating its safety and efficacy profiles along with its synergistic clinical benefits. Niacinamide treatment decreased serum phosphorus from 6.26 to 5.47 mg/DL ( lessThan i greaterThan P lessThan /i greaterThan = .02), and no significant changes occurred in the placebo group. Among patients who demonstrated more than 80% adherence based on routine pill counts, the fall in serum phosphorus was more pronounced, decreasing from 6.45 to 5.28 mg/DL ( lessThan i greaterThan P lessThan /i greaterThan =. 002). . Thus, Niacin can be a patient-convenient and inexpensive alternative or adjunctive therapy for phosphorus management in dialysis patients.
DR SEEMA MISHRA *
niacin, nicotinic acid, niacinamide, hyperphosphatemia, C-peptide,dialysis.
317-323